Quarterly report pursuant to Section 13 or 15(d)

Commitment and Contingencies - Additional Information (Details)

v3.20.2
Commitment and Contingencies - Additional Information (Details)
 9 Months Ended
Sep. 30, 2020
USD ($)
$ / RNL
Sep. 08, 2020
USD ($)
Jan. 21, 2020
USD ($)
Nov. 18, 2015
USD ($)
Royalty-Linked Notes        
Other Commitments [Line Items]        
Debt instrument outstanding portion | $ / RNL 0.04      
Debt instrument maturity date Dec. 31, 2045      
Debt instrument, aggregate potential payment capped value $ 160,000      
Debt instrument, aggregate potential payment capped rate 4,000      
Royalty-Linked Notes | Private Placement        
Other Commitments [Line Items]        
Aggregate principal amount     $ 2,579,400  
Royalty-Linked Notes | Rights Offering        
Other Commitments [Line Items]        
Aggregate principal amount   $ 11,000    
Pfizer License Agreement | Royalty-Linked Notes        
Other Commitments [Line Items]        
Debt instrument outstanding portion | $ / RNL 0.04      
Debt instrument maturity date Dec. 31, 2045      
Debt instrument, aggregate potential payment capped value $ 160,000      
Debt instrument, aggregate potential payment capped rate 4,000      
Pfizer License Agreement | Royalty-Linked Notes | Private Placement        
Other Commitments [Line Items]        
Aggregate principal amount     $ 2,579,400  
Pfizer License Agreement | Royalty-Linked Notes | Rights Offering        
Other Commitments [Line Items]        
Aggregate principal amount   $ 11,000    
Pfizer License Agreement | Minimum        
Other Commitments [Line Items]        
Potential future regulatory milestone and sales milestone payments upon achievement of net sales       $ 250,000,000
Pfizer License Agreement | Maximum        
Other Commitments [Line Items]        
Potential future regulatory milestone and sales milestone payments upon achievement of net sales       $ 1,000,000,000